{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-178569","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.219619+00:00","generated_at":"2026-06-13T14:41:35.864439+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 14 special meeting","bullets":["Board reiterates recommendation to approve merger with Infinity Pharmaceuticals (INFI) at July 14 special meeting.","Combined pipeline includes three clinical-stage programs: eganelisib, voruciclib (with Venclexta), and ME-344 (with Avastin).","Key data expected from voruciclib and ME-344 by year-end 2023; eganelisib is a Phase 2 first-in-class PI3K-gamma inhibitor.","Combined company will have experienced drug development team and is positioned to advance diversified oncology pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-178569","json":"https://secwatch.observer/filing/0001193125-23-178569.json","markdown":"https://secwatch.observer/filing/0001193125-23-178569.md","text":"https://secwatch.observer/filing/0001193125-23-178569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523178569/0001193125-23-178569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523178569/d461231d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:41:35.864439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}